Reference
- Ostrosky-Zeichner L. New approaches to the risk of candida in the intensive care unit. Curr. Opin. Infect. Dis. 16,533–537 (2003).
- Pappas PG, Rex JH, Sobel JD, et al Guidelines for the treatment of candidiasis. Clin. Infect. Dis. 38,161–189 (2004).
- •Helpful review for clinicians, sanctioned by the Infectious Diseases Society of America.
- Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin. Infect. Dis. 37\(Suppl. 3), 5157—S187 (2003).
- Denning DW. Echinocandin antifungal drugs. Lancet 362,1142-1151 (2003).
- •Excellent review of this class ofantifungal agents.
- Turner WW Current WL. Echinocandin antifungal agents. In: Biotechnology of Industrial Antibiotics,Second Edition. Strohl WR (Ed.), Marcel Dekker, NY, USA (1997).
- Debono M, Turner WW, LaGrandeur L, et al. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J. Med. Chem. 38,3271–3281 (1995).
- Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY-303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45,2845–2855 (2001).
- •Describes the assay used to quantify anidulafungin concentrations in biological fluids.
- Debono M, Abbott BJ, Turner JR, et al. Synthesis and evaluation of LY-121019, a member of a series of semisynthetic analogs of the antifungal lipopeptide echinocandin B. Ann. 1VY Acad. Sci. 544,152-167 (1988).
- Pfaller MA, Hollis R, Goldstein BR, Messer S, Diekema D, Henkel T. In vitro activity of anidulafungin (ANID) and other agents against 526 esophageal candidiasis (EC) isolates. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2003) (Abstract M–1226).
- Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2000 bloodstream candida isolates in the USA. Antimicrob. Agents Chemother. 10, 3149–3154 (2003).
- •Latest and largest compilation of antifungal susceptibility data.
- Johnson EM, Goldstein BR, Davey KG, Fraser MA. Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole against a panel of 780 yeasts obtained from five European centres. Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (2004) (Abstract CZ 513).
- Del Carmen Serrano M, Valerde-Conde A, Chavez M, et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY-303366) and amphotericin B against Aspergillus spp. Diag. Microbial Infect. Dis. 45,131–135 (2003).
- Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48,1382–1383 (2004).
- Thye D, Shepherd B, White RJ, Weston IE, Henkel T. Anidulafungin: a Phase 1 study to identify the maximum tolerated dose in healthy volunteers. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2001) (Abstract A–36).
- •Established the loading dose:maintenance dose ratio of 2: 1.
- Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T A population pharmacokinetic analysis of anidulafungin. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2003) (Abstract A–1575).
- Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44,590–598 (2004).
- Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY-303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43, 2148–2155 (1999).
- Hoban D, Balko T, Saunders D, Kabani A, Karlowsky J, Zhanel G. Influence of human serum on Candida spp. susceptibility to LY-303366. Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (1998) (Abstract J–9).
- Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases (2003) (Abstract P1223).
- • Helped demonstrate that anidulafungin does not undergo enzymatic transformation.
- Dowell JA, Pu F, Lee J, Stogniew M, Krause D, Henkel T A clinical mass balance study of anidulafungin showing complete fecal elimination. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2003) (Abstract A–1576).
- Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases (2003) (Abstract P1222).
- •Results of this investigation show thatdosage adjustments are not necessary in patients with renal or hepatic dysfunction.
- Herbrecht R, Graham D, Schuster M, et al Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA). Program and Abstracts of Tandem Bone Marrow Transplantation Meetings (2003) (Abstract 251).
- Krause DS, Reinhardt J, Vazquez JA, et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48, 2021–2024 (2004).
- Schranz J, Krause D, Goldstein BP, Henkel T Efficacy of anidulafungin for the treatment of Candidemia. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2003) (Abstract M–971).
- Krause D, Schranz J, Birmingham W Safety results from a Phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs. fluconazole (FLU) in patients with esophageal candidiasis (EC). Program and abstracts of 41st Meeting of the Infectious Disease Society of America (2003) (Abstract 36).
- •Largest compilation of data published todate regarding the safety and adverse effects of anidulafungin.
- Krause D, Schranz J, Birmingham W Lack of hepatic effect of anidulafungin (ANID). Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (2004) (Abstract 1789).
- Stogniew M, Dowell JA, Krause D, Henkel T. Population pharmacokinetics (PK) confirms absence of anidulafungin (ANID) drug—drug interactions. Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (2004) (Abstract CZ 1035).
- Schranz J, Dowell J, Krause D, Henkel T Anidulafungin and cyclosporin: safe coadministration without dosing adjustment. Program and abstracts of the 15th Congress of the International Society for Human and Animal Mycology (2003) (Abstract 399.2).
- White RJ, Thye D. Anidulafungin does not affect the metabolism of cyclosporin by human hepatic microsomes. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2001) (Abstract A–35).
- Krause D, Kilfoil T, Kilfoil G, Henkel T Anidulafungin: safety and pharmacokinetics in subjects receiving concomitant cyclosporin. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2002) (Abstract A–1836).
- Dowell J, Schranz J, Wilson J, Baruch A, Foster G. Anidulafungin (ANID) pharmacokinetics are not affected by concomitant voriconazole (VORI). Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases. (2004) (Abstract 1034).
- Dowell J, Schranz J, Stogniew M, Krause D, Henkel T Assessment of the pharmacokinetics (PK) of anidulafungin (ANID) in patients with invasive aspergillosis (IA) receiving concomitant liposomal amphotericin B (LAmB). Program and abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases (2004) (Abstract CZ 1036).
- Stone J, Holland S, Wickersham P, et al. Drug interactions between caspofungin and tacrolimus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2002) (Abstract A–13).
- Stone JA, Migoya E, Hickey L, et al. Drug interactions between caspofungin and nelfinavir or rifampin. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2003) (Abstract A–1605).
- Stone JA, Li S, Winchell G, et al. Population pharmacokinetics of caspofungin in candidiasis patients. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Abstracts of the American Society for Microbiology (2003) (Abstract A–1571).
- Kaneko H, Yamato Y, Hashimoto T, et al. Drug interactions of micafungin in vitro. Jpn J. Chemother. 50\(Suppl. 1), 94–103 (2002).
Websites
- Toscano CM, Jarvis WR. Epidemiology and clinical aspects of unusual fungal nosocomial infections. www.nfid.org/publications/clinicalupdate s/fungal/noso.html (Accessed July 2004)
- Flockhart DA. Drugs metabolized by known P450's. Indiana School of Medicine. medicine.iupui.edufflockhart/table.htm (Accessed July 2004)
- •A comprehensive guide to drugs that may be substrates, inducers or inhibitors of cytochrome P450 enzymes.